
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type based on the provided ranked marker list from a single-cell human dataset derived from breast cancer tissue, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **MS4A1 (CD20)**: A well-known marker for B cells, involved in B cell activation and proliferation.<br>- **CD19**: A critical component of the B cell receptor complex, essential for B cell signaling.<br>- **BLK**: A tyrosine kinase involved in B cell receptor signaling.<br>- **CD79A and CD79B**: Components of the B cell receptor complex, crucial for B cell development and signaling.<br>- **BANK1**: A B cell scaffold protein that modulates B cell receptor signaling.<br>- **PTPRCAP (CD45-AP)**: Associated with leukocyte common antigen, involved in B cell receptor signaling.<br>- **CD52**: A glycoprotein expressed on the surface of mature lymphocytes, including B cells.<br>- **POU2F2 (OCT2)**: A transcription factor involved in B cell development and function.<br>- **IGMH**: Immunoglobulin heavy constant mu, part of the B cell receptor complex.<br>- **HLA-DRB5, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DRA, HLA-DQB1, HLA-DRB1, HLA-DMA**: MHC class II molecules, important for antigen presentation in immune cells, including B cells.<br><br>### Step 2: List the Key Cell Type Markers<br>- **MS4A1 (CD20)**, **CD19**, **CD79A**, **CD79B**, **BANK1**, **IGMH**: These markers are highly specific to B cells, indicating a B cell lineage.<br>- **HLA-DRB5**, **HLA-DPA1**, **HLA-DPB1**, **HLA-DQA1**, **HLA-DRA**, **HLA-DQB1**, **HLA-DRB1**, **HLA-DMA**: These are indicative of antigen-presenting cells, which include B cells.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Cell Atlas and literature on scRNA-seq datasets, the expression of markers like MS4A1, CD19, CD79A, and CD79B strongly suggests a B cell identity. These markers are consistently used to identify B cells in various scRNA-seq studies.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of key markers such as MS4A1, CD19, CD79A, and CD79B, the most probable general cell type is **B cells**.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **Naive B Cells**: Characterized by the expression of CD19, CD79A, and CD79B, along with MHC class II molecules, indicating a role in antigen presentation.<br>2. **Memory B Cells**: These cells also express CD19 and CD79A but may have a slightly different expression profile, often with higher levels of MHC class II molecules.<br>3. **Plasma Cells**: While not directly indicated by the markers, the presence of immunoglobulin heavy chain (IGHM) suggests a potential for differentiation into antibody-secreting cells.<br><br>The most likely subtype based on the markers is **Naive B Cells**, given the strong expression of CD19, CD79A, and MHC class II molecules without additional markers for plasma cell differentiation.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset indicates that the cell cluster is most likely composed of B cells. The expression of key B cell markers such as MS4A1, CD19, CD79A, and CD79B, along with MHC class II molecules, supports this annotation. Among B cells, the most probable subtype is Naive B Cells, given the expression profile and lack of differentiation markers for plasma cells.<br><br>**FINAL ANNOTATION COMPLETED**
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - The key markers used for annotation, such as MS4A1 (CD20), CD19, CD79A, CD79B, BANK1, and IGHM, are present in the provided marker list. These markers are well-known and specific to B cells, supporting the annotation of the cell type as B cells.<br>   - The presence of MHC class II molecules (HLA-DRB5, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DRA, HLA-DQB1, HLA-DRB1, HLA-DMA) further supports the identification of these cells as antigen-presenting B cells.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The analysis does not strongly suggest the presence of multiple distinct cell types within the cluster. The markers predominantly indicate a B cell identity, with no strong evidence for other cell types based on the high-ranking markers provided.<br>   - The potential subtypes (Naive B Cells, Memory B Cells, and Plasma Cells) are all within the B cell lineage, and the annotation appropriately identifies Naive B Cells as the most probable subtype based on the expression profile.<br><br>Overall, the annotation is well-supported by the marker list and aligns with known B cell markers, leading to a valid conclusion of the cell type as B cells, specifically Naive B Cells.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">B cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>Naive B Cells</li><li>Memory B Cells</li><li>Plasma Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided are generally well-executed, with a strong focus on identifying B cells as the primary cell type based on the marker list. The analysis correctly identifies key B cell markers such as MS4A1 (CD20), CD19, CD79A, and CD79B, which are highly specific to B cells and are appropriately used to determine the main cell type. The inclusion of MHC class II molecules further supports the identification of these cells as antigen-presenting B cells, which is consistent with the known biology of B cells.<br><br>The annotation also considers potential subtypes within the B cell lineage, identifying Naive B Cells as the most probable subtype. This is a reasonable conclusion given the expression of CD19, CD79A, and MHC class II molecules, and the lack of markers indicating plasma cell differentiation. The consideration of Memory B Cells and Plasma Cells as possible subtypes shows a comprehensive approach to the analysis.<br><br>However, there are a few areas where the analysis could be improved. While the annotation does not suggest the presence of multiple distinct cell types, it could have explored the possibility of mixed cell populations more thoroughly, especially given the complex nature of breast cancer tissue. Additionally, the analysis could have placed more emphasis on the rank of the markers, as the order of marker appearance can provide insights into their relative importance.<br><br>Overall, the annotation is scientifically accurate and provides a balanced consideration of multiple markers, capturing the general picture of the cell populations present. There are no obvious misclassifications, and the analysis aligns well with known B cell biology.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    